Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
167
Recruiting, industry sponsors, Cardiovascular and metabolic, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting167
- Completed1,732
167 trials
Showing 1 to 25, recently updated first.
- Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)Pivotal-lookingRecruiting
Foresee Pharmaceuticals Co., Ltd.Industry
NCT06475781 · 126 participants (planned) · Start Mar 1, 2025 · Primary completion Feb 2028
Drug: Mirivadelgat; placebo · For: Group 3 Pulmonary Hypertension
Sites: Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina; Tbilisi, Georgia · 15 sites in all
Atrium TherapeuticsIndustry
NCT07738107 · 37 participants (planned) · Start Sep 14, 2026 · Primary completion May 2028
Drug: ATR 1072 · For: Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic and 1 more
Sites: Kansas City, Missouri; Houston, Texas
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07685808 · 360 participants (planned) · Start Jul 28, 2026 · Primary completion Jan 21, 2028
Drug: Olatorepatide; Placebo · For: Overweight or Obesity
Sites: Mobile, Alabama; Walnut Creek, California; Waterbury, Connecticut · 22 sites in all
- GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)Recruiting
Eddingpharm (Zhuhai) Co., Ltd.Industry
NCT07738341 · 270 participants (planned) · Start Jul 28, 2026 · Primary completion Aug 1, 2029
Drug: GB268; Nab-Paclitaxel and 2 more · For: Breast Cancer (Locally Advanced or Metastatic)
Sites: Beijing, China
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Industry
NCT06965621 · 20 participants (planned) · Start Nov 5, 2025 · Primary completion Mar 30, 2027
Drug: 18F-metaFluorobenzylguanidine; Rubidium-82 · For: Heart Failure; Ischemic Cardiomyopathy; ICD Patients
Sites: Houston, Texas
- SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .Pivotal-lookingRecruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07940075 · 360 participants (planned) · Start Aug 11, 2026 · Primary completion Jan 31, 2027
Drug: SYH2062; Placebo · For: Mild to Moderate Primary Hypertension
Sites: Beijing, China
AllRock Bio, Inc.Industry
NCT07175038 · 40 participants (planned) · Start Oct 1, 2025 · Primary completion Mar 2027
Drug: ROC-101 · For: Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension, Interstitial Lung Disease
Sites: Phoenix, Arizona; Rancho Cordova, California; Aurora, Colorado · 25 sites in all
Op-T LLCIndustry
NCT06964087 · 72 participants (planned) · Start Apr 23, 2026 · Primary completion May 31, 2027
Drug: OPT101 · For: Type I Diabetes
Sites: Birmingham, Alabama; Walnut Creek, California; Aurora, Colorado · 5 sites in all
- A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityPivotal-lookingRecruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07243171 · 126 participants (planned) · Start Nov 18, 2025 · Primary completion Jan 5, 2027
Drug: ecnoglutide tablets; placebo with matching dosage and 2 more · For: Overweight and/or Obesity; Weight Management
Sites: Beijing, China
Novartis PharmaceuticalsNovartis (NVS)
NCT07543120 · 323 participants (planned) · Start May 7, 2026 · Primary completion May 7, 2031
Drug: QCZ484 · For: Hypertension (HTN)
Sites: Andalusia, Alabama; Tucson, Arizona; Garden Grove, California · 46 sites in all
- CRF2 Agonist for the Treatment of Worsening Heart FailurePivotal-lookingRecruiting
Corteria PharmaceuticalsIndustry
NCT06815471 · 210 participants (planned) · Start Aug 7, 2025 · Primary completion Jul 2027
Drug: COR-1167; Placebo · For: Worsening Heart Failure
Sites: Indianapolis, Indiana; Detroit, Michigan; Greensboro, North Carolina · 55 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07748208 · 40 participants (planned) · Start Nov 30, 2026 · Primary completion Jun 15, 2029
Drug: Inavolisib; Fulvestrant and 1 more · For: Breast Cancer; Diabetes Type II
Sites: Clovis, California; Torrance, California; Washington D.C., District of Columbia · 13 sites in all
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamagePivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07770685 · 156 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 31, 2030
Drug: ASP2767; Sham ASP2767 and 3 more · For: Glaucoma
Sites: Boston, Massachusetts
- Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05714085 · 342 participants (planned) · Start May 31, 2023 · Primary completion Aug 20, 2029
Drug: Vericiguat tablet; Vericiguat suspension and 2 more · For: Heart Failure; Left Ventricular Systolic Dysfunction
Sites: Los Angeles, California; Palo Alto, California; San Bernardino, California · 112 sites in all
- A Study to Evaluate ALN-2232 in Participants With ObesityPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07463846 · 156 participants (planned) · Start Mar 2, 2026 · Primary completion Apr 28, 2027
Drug: ALN-2232; Placebo and 1 more · For: Obesity
Sites: Mount Royal, Canada
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07553442 · 93 participants (planned) · Start Apr 27, 2026 · Primary completion Apr 1, 2028
Drug: ALN-AGT01 RVR; Placebo and 1 more · For: Hypertension
Sites: Lake Forest, California; Tampa, Florida; Savannah, Georgia
- A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06321302 · 175 participants (planned) · Start May 15, 2024 · Primary completion Mar 5, 2027
Drug: BI 764524; Sham comparator to BI 764524 and 1 more · For: Diabetic Retinopathy
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 90 sites in all
- Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are OverweightPivotal-lookingRecruiting
Hudson BiotechIndustry
NCT07467447 · 300 participants (planned) · Start Feb 15, 2026 · Primary completion Mar 14, 2027
Drug: Retatrutide (LY3437943); Placebo · For: Obesity
Sites: Shenzhen, China
- A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With HypertensionRecruiting
CRISPR Therapeutics AGIndustry
NCT07758634 · 69 participants (planned) · Start Sep 25, 2026 · Primary completion Jul 1, 2028
Drug: CTX340; Placebo · For: Hypertension
Sites: Jacksonville, Florida; Orlando, Florida; Port Orange, Florida · 11 sites in all
Sinotau Pharmaceutical GroupIndustry
NCT07443696 · 40 participants (planned) · Start Dec 18, 2025 · Primary completion Dec 31, 2026
Drug: Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging; Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging · For: Ischemic Cardiomyopathy; Heart Failure
Sites: Beijing, China; Tianjin, China · 3 sites in all
- A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart FailurePivotal-lookingRecruiting
AnaCardio ABIndustry
NCT07584967 · 400 participants (planned) · Start Nov 15, 2026 · Primary completion Jul 30, 2028
Drug: AC01 · For: Heart Failure With Reduced Ejection Fraction (HFrEF)
Sites: Van Nuys, California; Crystal River, Florida; Schaumburg, Illinois · 14 sites in all
- Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerPivotal-lookingRecruiting
Solstice Oncology, Inc.Industry
NCT07808151 · 100 participants (planned) · Start Nov 30, 2026 · Primary completion Sep 30, 2029
Drug: Pembrolizumab; Porustobart · For: Colon Cancer
Sites: Los Angeles, California; Tampa, Florida; Chicago, Illinois · 30 sites in all
- A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07058077 · 153 participants (planned) · Start Aug 21, 2025 · Primary completion Dec 4, 2033
Drug: Enlicitide Decanoate; Placebo · For: Heterozygous Familial Hypercholesterolemia (HeFH)
Sites: Wilmington, Delaware; Washington D.C., District of Columbia; Boca Raton, Florida · 50 sites in all
COUR Pharmaceutical Development Company, Inc.Industry
NCT06783309 · 72 participants (planned) · Start May 12, 2025 · Primary completion Aug 2027
Drug: CNP-103; Placebo · For: Type 1 Diabetes Mellitus; T1D; T1DM and 7 more
Sites: Tucson, Arizona; Newport Beach, California; San Diego, California · 45 sites in all
- A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 DiabetesPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07112872 · 330 participants (planned) · Start Aug 19, 2025 · Primary completion Feb 5, 2028
Drug: Tifeglipron; Semaglutide and 1 more · For: Type 2 Diabetes Mellitus
Sites: Tucson, Arizona; Lake Forest, California; Rancho Cucamonga, California · 51 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.